Webinar

Join us on June 21st to participate in our joint webinar with Labcorp Drug Development “Overcoming the challenges in deploying new imaging biomarkers in clinical trials – Perspectives from patients, physicians and other stakeholders”. Want to know more? Register now!

Register here

Median's latest news

Fredrik Brag, CEO and founder of Median, provides additional insights on iBiopsy ® Lung Cancer Screening CADe/CADx Software as Medical Device (in French).

Watch video

Latest press releases

23 May 2022

Median Technologies announces the availability of the preparatory documents for the Shareholders’ Ordinary and Extraordinary General Meeting on June 14, 2022

The shareholders of Median Technologies (ALMDT:PA) are invited to participate at the Shareholders’ Ordinary and Extraordinary General Meeting which will be held on Tuesday June 14, 2022, at 5:00 PM at PDGB, 174 avenue Victor Hugo – 75116 Paris.

5 May 2022

Median Technologies is moving forward with the FDA interactions for its iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device

Median has received the FDA’s feedback following the 513(g) regulatory submission for its iBiopsy® LCS CADe/CADx Software as Medical Device. Median will proceed through a 510(k) submission to obtain an FDA device clearance and market authorization, targeted for end 2023. On May 2, 2022, Median initiated a Q-submission process, composed of several submissions, to request feedback from the FDA on various topics such as the pivotal study protocols.

21 April 2022

Median Technologies reports full-year 2021 results and business indicators for the first quarter of 2022

Record high revenue of €5.7 million in Q1 2022, up 9.2% compared with Q1 2021 – Further growth in the order backlog to €62.3 million as of March 31, 2022, up 18.4% compared with March 31, 2021- Revenue of €20.5 million as of December 31, 2021, up 52.4% compared to December 31, 2020 – Cash and cash equivalents of €33.1 million as of March 31, 2022

22 March 2022

Median Technologies announces design completion of its iBiopsy® Lung Cancer Screening end-to-end CADe/CADx Software as Medical Device (SaMD) with outstanding sensitivity & specificity performance

iBiopsy® Lung Cancer Screening (LCS) CADe/CADx outstanding performance reaches 94.7% sensitivity[2] at 93.3% specificity, based on a cohort of 1,760 patients. With such performance, iBiopsy® LCS CADe/CADx SaMD positions itself to dramatically increase the efficacy of lung cancer screening programs worldwide, which would facilitate saving the lives of millions.

9 March 2022

Disclosure of total number of voting rights and number of shares in the capital as of February 28th, 2022

Disclosure of total number of voting rights and number of shares in the capital as of February 28th, 2022, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

1/5

Our Winter Corporate Newsletter

We are pleased to share with you our Winter Corporate Newsletter, presenting our most recent announcements and what we did during the fourth quarter of 2021 and in early Q1 2022. Click below to read the Newsletter!

Webinars

JUNE 21st, 2022

Overcoming the challenges in deploying new imaging biomarkers in clinical trials – Perspectives from patients, physicians and other stakeholders

New Imaging biomarkers have a strong potential to provide additional insight for clinical trials: better selection of patients, prediction of response to therapy, early assessments of drug effects and safety. However, implementing them in clinical trials often promote challenges.

The aim of this webinar is to discuss these challenges from the perspective of patients, physicians and the different stakeholders involved in the oncology clinical trials. Want to know more? Register now!

Imaging for clinical trials

Advancing treatments of the future

Working with biopharma companies and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments.

Read more

iBiopsy®

Enhancing imaging diagnostic accuracy

Our team of data scientists, AI engineers and clinicians is focused on developing the most accurate and cutting-edge AI-powered Software as a Medical Device (SaMD). iBiopsy® targets: lung cancer, liver cancer, and NASH to provide to patients an earlier and optimal diagnosis avoiding unnecessary invasive tests.

Read more

Investors

Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Stock Market Data

TICKER: ALMDT ISIN: FR0011049824
Get in touch

Together, let's build the future of medicine

Contact us Jobs at Median